HAVN Life Sciences Inc. reported earnings results for the third quarter and nine months ended January 31, 2023. For the third quarter, the company reported negative sales was CAD 0.01206 million compared to sales of CAD 0.023025 million a year ago. Net loss was CAD 0.691538 million compared to CAD 2.19 million a year ago. Basic loss per share from continuing operations was CAD 0.07 compared to CAD 0.52 a year ago.
For the nine months, sales was CAD 0.370597 million compared to CAD 0.060094 million a year ago. Net loss was CAD 4.34 million compared to CAD 11.08 million a year ago. Basic loss per share from continuing operations was CAD 0.55 compared to CAD 2.69 a year ago.